Corgenix Expands Scientific Advisory Board
17 Juni 2008 - 11:15AM
PR Newswire (US)
DENVER, June 17 /PRNewswire-FirstCall/ -- Corgenix Medical
Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a worldwide
developer and marketer of diagnostic test kits, announced today the
appointment of Barry L. Molk, M.D., F.A.C.C., and Charles H.
Miranda, M.D., F.A.C.P., F.A.A.P., to its scientific advisory
board. Drs. Molk and Miranda join Luis Lopez, M.D., Corgenix
Chairman and Chief Medical Officer, expanding the number of
scientific advisory board members to three. "These two individuals
bring a wealth of knowledge and expertise to our organization,"
said Douglass Simpson, Corgenix' President and Chief Executive
Officer. "Their appointment strengthens the clinical and scientific
guidance required for the successful development, manufacturing and
marketing of our diagnostic testing products." Dr. Molk has been
affiliated with Aurora Denver Cardiology Associates since 1976 and
has served as Chief of Cardiology at Sky Ridge Medical Center since
2003. He is board certified in internal medicine and cardiovascular
diseases and is also a Fellow of the American College of Cardiology
(F.A.C.C.). After receiving his medical degree from the University
of Colorado Health Sciences Center (UCHSC), Dr. Molk completed his
residency training at Baylor Affiliated Hospitals and UCHSC, and is
fellowship trained in cardiology from UCHSC. He maintains a
teaching appointment as Associate Clinical Professor of Medicine,
UCHSC. Dr. Miranda is currently in private practice in internal
medicine and pediatrics at South Denver Internal Medicine and
Pediatrics, P.C. in Denver. Previously, he practiced internal
medicine and pediatrics for 10 years at the world-renowned Texas
Medical Center in Houston. Miranda is board certified by the
American Board of Internal Medicine and the American Board of
Pediatrics. He is a Fellow of the American Academy of Pediatrics
(F.A.A.P.) and the American College of Physicians (F.A.C.P.). Dr.
Miranda received his medical degree from the University of
California, San Francisco (UCSF). He completed specialty training
in both internal medicine and pediatrics at Baylor College of
Medicine in Houston, Texas. He is also a clinical instructor in the
department of medicine at UCHSC. Corgenix periodically draws on the
expertise of advisors and consultants in fields related to its
technology and markets. These members are available to Corgenix as
needed on an individual basis to provide advice with respect to
clinical medicine and other matters requiring scientific expertise.
Non-employee members of the scientific advisory board are
compensated for their participation. About Corgenix Medical
Corporation Corgenix is a leader in the development and
manufacturing of specialized diagnostic kits for immunology
disorders, vascular diseases and bone and joint disorders. Corgenix
diagnostic products are commercialized for use in clinical
laboratories throughout the world. The company currently sells over
50 diagnostic products through a global distribution network. More
information is available at http://www.corgenix.com/. Statements in
this press release that are not strictly historical facts are
"forward-looking" statements (identified by the words "believe",
"estimate", "project", "expect" or similar expressions) within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements inherently involve risks and uncertainties that
could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute
to such differences include, but are not limited to, continued
acceptance of the Company's products and services in the
marketplace, competitive factors, changes in the regulatory
environment, and other risks detailed in the Company's periodic
report filings with the Securities and Exchange Commission. The
statements in this press release are made as of today, based upon
information currently known to management, and the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements. DATASOURCE: Corgenix Medical
Corporation CONTACT: William Critchfield, Senior VP and CFO of
Corgenix Medical Corporation, +1-303-453-8903, ; or Media, Dan
Snyders, Vice President, Public Relations Supervisor of Armada
Medical Marketing, +1-303-623-1190, ext. 230, , for Corgenix
Medical Corporation Web site: http://www.corgenix.com/
Copyright